Hypokalemia from Beta2-Receptor Stimulation by Circulating Epinephrine

New England Journal of Medicine

Volumn 309, Issue 23, 1983, Pages 1414-1419

  Brown, M J ^a   Brown, D C ^b   Murphy, M B ^b  

^a MIDDLESEX HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ISOPRENALINE; PLACEBO; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA ADRENERGIC RECEPTOR; INSULIN; NORADRENALIN; POTASSIUM; PROPANOLAMINE DERIVATIVE; RENIN;

AUTONOMIC NERVOUS SYSTEM; BETA 2 ADRENERGIC RECEPTOR STIMULATION; BLOOD AND HEMOPOIETIC SYSTEM; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEART; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; HYPOKALEMIA; INSULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; TACHYCARDIA; ADULT; ARTICLE; BLOOD; DRUG EFFECT; HEART RATE; MALE; PHYSIOLOGY;

ADULT; EPINEPHRINE; HEART RATE; HUMAN; HYPOKALEMIA; INSULIN; ISOPROTERENOL; MALE; NOREPINEPHRINE; POTASSIUM; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA; RENIN; SUPPORT, NON-U.S. GOV'T;

EID: 0020975294     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198312083092303     Document Type: Article

References (43)

1. D'Silva JL. The action of adrenaline on serum potassium. J Physiol (Lond) 1934; 82: 393–398.
2. Todd EP, Vick RL. Kalemotropic effect of epinephrine: analysis with adrenergic agonists and antagonists. Am J Physiol 1971; 220: 1964–1969.
3. Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980; 302: 431–434.
4. DeFronzo RA, Bia M, Birkhead G. Epinephrine and potassium homeostasis. Kidney Int 1981; 20: 83–91.
5. Clausen T, Flatman JA. β2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K transport in rat soleus muscle. Br J Pharmacol 1980; 68: 749–755.
6. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597–598.
7. Hales CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J 1963; 88: 137–146.
8. Brown MJ, Jenner DA. Novel double-isotope technique for enzymatic assay of catecholamines, permitting high precision, sensitivity and plasma sample capacity, Clin Sci 1981; 61: 591–598.
9. Carlsson E, Fellenius E, Lundborg P, Svensson L. β-adrenoeeptor blockers, plasma-potassium, and exercise. Lancet 1978; 2: 424–425.
10. Karlsberg RP, Cryer PE, Roberts R. Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J 1981; 102: 24–29.
11. Mueller HS, Ayres SM. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Invest 1980; 65: 338–346.
12. Dyckner T, Helmers C, Lundman T, Wester PO. Initial serum potassium level in relation to early complications and prognosis in patients with acute myocardial infarction. Acta Med Scand 1975; 197: 207–210.
13. Johansson BW, ed. Electrolytes and cardiac arrhythmias. Acta Med Scand [Suppl] 1981; 647: 1–177.
14. Duke M. Thiazide-induced hypokalemia associated with acute myocardial infarction and ventricular fibrillation. JAMA 1978; 239: 43–45.
15. Flear CTG, Hilton P. Hyponatraemia and severity and outcome of myocardial infarction. Br Med J 1979; 1: 1242–1246.
16. Harrington JT, Isner JM, Kassirer JP. Our national obsession with potassium. Am J Med 1982; 73: 155–159.
17. Gettes LS, Surawicz B, Kim KH. Role of myocardial K and Ca in initiation of ventricular fibrillation. Am J Physiol 1966; 211: 699–702.
18. Curry P, Fitchett D, Stubbs W, Krikler D. Ventricular arrhythmias and hypokalemia. Lancet 1976; 2: 231–233.
19. Challoner DR, Steinberg D. Effect of free fatty acid on the oxygen consumption of perfused rat heart. Am J Physiol 1966; 210: 280–286.
20. Rosell S, Axelrod J, Kopin IJ. Release of tritiated epinephrine following sympathetic nerve stimulation. Nature 1964; 201: 301
21. Brown MJ, Dollery CT. Adrenaline and hypertension. Clin Exp Hypertens (in press).
22. Iversen LL. The uptake and storage of noradrenaline in sympathetic nerves. Cambridge, England: Cambridge University Press, 1967.
23. Clutter WE, Bier DM, Shah SD, Cryer PE. Epinephrine plasma metabolic clearance rate and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest 1980; 66: 94–101.
24. Mathias CJ, Frankell HL, Davies IB, James VHT, Peart WS. Renin and aidosterone release during sympathetic stimulation in tetraplegia. Clin Sci 1981; 60: 399–404.
25. Pettit GW, Vick RL. An analysis of the contribution of the endocrine pancreas to the kalemotropic actions of catecholamines. J Pharmacol Exp Ther 1974; 190: 234–242.
26. Silva P, Spokes K, Epstein FH. Catecholamines and potassium homeostasis. Kidney Int 1977; 12: 544. abstract.
27. Olsson AM, Persson S, Schröder R. Effects of terbutaline and isoproterenol on hyperkalemia in nephrectomized rabbits. Scand J Urol Nephrol 1978; 12: 35–38.
28. Berend N, Marlin GE. Characterization of β-adrenoceptor subtype mediating the metabolic actions of salbutamol. Br J Clin Pharmacol 1978; 5: 207–211.
29. Bengtsson B, Fagerstrom P-O. Extrapulmonary effects of terbutaline during prolonged administration. Clin Pharmacol Ther 1982; 31: 726–732.
30. Smith SK, Thompson D. The effect of intravenous salbutamol upon plasma and urinary potassium during premature labour. Br J Obstet Gynaecol 1977; 84: 344–347.
31. Arnold JMO, Shanks RG, McDevitt DG. Beta-adrenoceptor antagonism of isoprenaline-induced metabolic changes in man. Br J Clin Pharmacol 1983; 15: 621P. abstract.
32. Bilski A, Dorries S, Fitzgerald JD, Jessup R, Tucker H, Wale J. ICI 118,551, a potent β2 adrenoceptor antagonist. Br J Pharmacol 1980; 69: pp. 292–293.
33. Harry JD, Young J, Stribling D. Effects of ICI 118551 (a β2-adrenoceptor blocker) on metabolic changes induced by isoprenaline and on tachycardia induced by exercise. Br J Clin Pharmacol 1982; 14: p. 584–585.
34. Harry JD, Norris SC, Percival PG, Young J. Effects in man of ICI 118551 (a β2-adrenoceptor antagonist) on some cardiovascular actions of dobutamine. Br J Clin Pharmacol (in press).
35. Bühler FR, Burkart F, Lütold BE, Küng M, Marbet G, Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 1975; 36: 653–669.
36. Steiness E. Negative potassium balance during beta-blocker treatment of hypertension. Clin Pharmacol Ther 1982; 31: 691–694.
37. Hampton JR. Should every survivor of a heart attack be given a beta blocker? I. Evidence from clinical trials. Br Med J 1982; 285: 33–36.
38. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1: 1142–1147.
39. Yusuf S, Ramsdale D, Peto R, et al. Early intravenous atenolol treatment in suspected acute myocardial infarction: preliminary report of a randomised trial. Lancet 1980; 2: 273–276.
40. Silverberg AB, Shah SD. Haymond MW, Cryer PE. Norepinephrine: hormone and neurotransmitter in man. Am J Physiol 1978; 234: E252–E256.
41. Scriven AJI, Dollery CT, Murphy MB, Macquin I, Brown MJ. Blood pressure and plasma norepinephrine concentrations after endogenous norepinephrine release by tyramine. Clin Pharmacol Ther 1983; 33: 710–716.
42. Carlsson E, Åblad B, Brändström A, Carlsson B. Differentiated blockade of the chronotropic effects of various adrenergic stimuli in the cat heart. Life Sci 1972; 11 (Part 1):953–958.
43. Struthers AD, Reid JL, Whitesmith R, Rodger JC. The effect of cardioselective and nonselective beta-adrenoceptor blockade on the hypokalemic and cardiovascular responses to adrenomedullary hormone in man. Clin Sci 1983; 65: 143–147.